DAVA freed from oxycodone liability
AVA Pharmaceuticals announced that it has settled a patent infringement suit with Impax Laboratories and Purdue Pharma regarding Impax's generic versions of Purdue's OxyContin.
Fort Lee, N.J.-based DAVA Pharmaceuticals announced that it has settled a patent infringement suit with Impax Laboratories and Purdue Pharma regarding Impax's generic versions of Purdue's OxyContin (oxycodone HCl controlled-release tablets). DAVA, its distributors, and customers were granted a full release from liability related to the sale and distribution of Impax-produced oxycodone products. Under the terms of the settlement, Impax was granted a license to sell the products through June 14, with rights to resume marketing in the near future of a limited amount of the products for a limited period of time.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
